JP2024152860A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024152860A5 JP2024152860A5 JP2024134396A JP2024134396A JP2024152860A5 JP 2024152860 A5 JP2024152860 A5 JP 2024152860A5 JP 2024134396 A JP2024134396 A JP 2024134396A JP 2024134396 A JP2024134396 A JP 2024134396A JP 2024152860 A5 JP2024152860 A5 JP 2024152860A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antitumor agent
- agent according
- pembrolizumab
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002246 antineoplastic agent Substances 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 229960002621 pembrolizumab Drugs 0.000 claims 8
- KEIPNCCJPRMIAX-HNNXBMFYSA-N 1-[(3s)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]pyrazolo[3,4-d]pyrimidin-1-yl]pyrrolidin-1-yl]prop-2-en-1-one Chemical compound COC1=CC(OC)=CC(C#CC=2C3=C(N)N=CN=C3N([C@@H]3CN(CC3)C(=O)C=C)N=2)=C1 KEIPNCCJPRMIAX-HNNXBMFYSA-N 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 6
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 6
- 201000004101 esophageal cancer Diseases 0.000 claims 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 201000009036 biliary tract cancer Diseases 0.000 claims 3
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 3
- 201000010536 head and neck cancer Diseases 0.000 claims 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 3
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- 238000011285 therapeutic regimen Methods 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019035603 | 2019-02-28 | ||
| JP2019035603 | 2019-02-28 | ||
| JP2019112619 | 2019-06-18 | ||
| JP2019112619 | 2019-06-18 | ||
| JP2021502662A JPWO2020175697A1 (https=) | 2019-02-28 | 2020-02-28 | |
| JP2023083174A JP2023096156A (ja) | 2019-02-28 | 2023-05-19 | ３，５－二置換ベンゼンアルキニル化合物とペムブロリズマブとを用いた癌治療法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023083174A Division JP2023096156A (ja) | 2019-02-28 | 2023-05-19 | ３，５－二置換ベンゼンアルキニル化合物とペムブロリズマブとを用いた癌治療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024152860A JP2024152860A (ja) | 2024-10-25 |
| JP2024152860A5 true JP2024152860A5 (https=) | 2025-03-13 |
Family
ID=72239799
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502662A Pending JPWO2020175697A1 (https=) | 2019-02-28 | 2020-02-28 | |
| JP2021502667A Pending JPWO2020175704A1 (https=) | 2019-02-28 | 2020-02-28 | |
| JP2023083174A Pending JP2023096156A (ja) | 2019-02-28 | 2023-05-19 | ３，５－二置換ベンゼンアルキニル化合物とペムブロリズマブとを用いた癌治療法 |
| JP2023102852A Pending JP2023112136A (ja) | 2019-02-28 | 2023-06-22 | ３，５－二置換ベンゼンアルキニル化合物と免疫チェックポイント阻害薬とを用いた癌治療法 |
| JP2024134396A Pending JP2024152860A (ja) | 2019-02-28 | 2024-08-09 | ３，５－二置換ベンゼンアルキニル化合物とペムブロリズマブとを用いた癌治療法 |
| JP2025024594A Pending JP2025075059A (ja) | 2019-02-28 | 2025-02-18 | ３，５－二置換ベンゼンアルキニル化合物と免疫チェックポイント阻害薬とを用いた癌治療法 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502662A Pending JPWO2020175697A1 (https=) | 2019-02-28 | 2020-02-28 | |
| JP2021502667A Pending JPWO2020175704A1 (https=) | 2019-02-28 | 2020-02-28 | |
| JP2023083174A Pending JP2023096156A (ja) | 2019-02-28 | 2023-05-19 | ３，５－二置換ベンゼンアルキニル化合物とペムブロリズマブとを用いた癌治療法 |
| JP2023102852A Pending JP2023112136A (ja) | 2019-02-28 | 2023-06-22 | ３，５－二置換ベンゼンアルキニル化合物と免疫チェックポイント阻害薬とを用いた癌治療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025024594A Pending JP2025075059A (ja) | 2019-02-28 | 2025-02-18 | ３，５－二置換ベンゼンアルキニル化合物と免疫チェックポイント阻害薬とを用いた癌治療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20220184082A1 (https=) |
| EP (2) | EP3932425A4 (https=) |
| JP (6) | JPWO2020175697A1 (https=) |
| KR (2) | KR20210130774A (https=) |
| AU (4) | AU2020228514B2 (https=) |
| MA (2) | MA55088A (https=) |
| TW (2) | TW202039507A (https=) |
| WO (2) | WO2020175704A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3424505A4 (en) | 2016-03-04 | 2019-10-16 | Taiho Pharmaceutical Co., Ltd. | PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS |
| US11883404B2 (en) | 2016-03-04 | 2024-01-30 | Taiho Pharmaceuticals Co., Ltd. | Preparation and composition for treatment of malignant tumors |
| SG11202008435SA (en) | 2018-03-19 | 2020-10-29 | Taiho Pharmaceutical Co Ltd | Pharmaceutical composition including sodium alkyl sulfate |
| AU2020352668A1 (en) * | 2019-09-26 | 2022-03-31 | Janssen Pharmaceutica Nv | Use of FGFR inhibitors in FGFR-genetically altered cancers to enhance patient response to immune checkpoint inhibitors in sequential treatment settings |
| WO2025046272A1 (en) | 2023-08-31 | 2025-03-06 | Taiho Pharmaceutical Co., Ltd. | Methods of treating cancer using futibatinib and pembrolizumab |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040004771A (ko) | 2002-07-05 | 2004-01-16 | 삼광유리공업주식회사 | 필름 코팅 유리컵 및 그 제조방법 |
| DK2657233T3 (da) * | 2012-01-19 | 2014-09-22 | Taiho Pharmaceutical Co Ltd | 3,5-disubstitueret alkynylbenzenforbindelse og salt deraf |
| KR101480809B1 (ko) | 2012-03-26 | 2015-01-09 | 한국화학연구원 | 리그닌-폴리에스테르 수지 혼합 분말의 제조 방법 및 이에 따라 제조되는 리그닌-폴리에스테르 수지 혼합 분말 |
| WO2015008844A1 (ja) * | 2013-07-18 | 2015-01-22 | 大鵬薬品工業株式会社 | Ｆｇｆｒ阻害剤耐性癌の治療薬 |
| AU2015327868A1 (en) * | 2014-10-03 | 2017-04-20 | Novartis Ag | Combination therapies |
| JP6572561B2 (ja) | 2015-03-03 | 2019-09-11 | ダイキン工業株式会社 | 熱交換器および空気調和機 |
| US10478494B2 (en) * | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| JP2018519327A (ja) * | 2015-06-29 | 2018-07-19 | ベラステム・インコーポレーテッドＶｅｒａｓｔｅｍ，Ｉｎｃ． | 治療用組成物、組合せ物および使用の方法 |
| US10149887B2 (en) * | 2015-10-23 | 2018-12-11 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment |
| US20170145103A1 (en) * | 2015-11-23 | 2017-05-25 | Five Prime Therapeutics, Inc. | Predicting response to cancer treatment with fgfr2 inhibitors |
| JP6409797B2 (ja) | 2016-02-24 | 2018-10-24 | 三菱電機株式会社 | 冷蔵庫 |
| EP3424505A4 (en) * | 2016-03-04 | 2019-10-16 | Taiho Pharmaceutical Co., Ltd. | PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS |
-
2020
- 2020-02-28 MA MA055088A patent/MA55088A/fr unknown
- 2020-02-28 AU AU2020228514A patent/AU2020228514B2/en active Active
- 2020-02-28 KR KR1020217030409A patent/KR20210130774A/ko not_active Ceased
- 2020-02-28 AU AU2020229714A patent/AU2020229714B2/en active Active
- 2020-02-28 EP EP20763207.6A patent/EP3932425A4/en active Pending
- 2020-02-28 JP JP2021502662A patent/JPWO2020175697A1/ja active Pending
- 2020-02-28 WO PCT/JP2020/008527 patent/WO2020175704A1/ja not_active Ceased
- 2020-02-28 US US17/434,655 patent/US20220184082A1/en active Pending
- 2020-02-28 JP JP2021502667A patent/JPWO2020175704A1/ja active Pending
- 2020-02-28 US US17/434,573 patent/US20220125793A1/en active Pending
- 2020-02-28 WO PCT/JP2020/008509 patent/WO2020175697A1/ja not_active Ceased
- 2020-02-28 EP EP20763687.9A patent/EP3932427A4/en active Pending
- 2020-02-28 MA MA055091A patent/MA55091A/fr unknown
- 2020-02-28 KR KR1020217030410A patent/KR20210131387A/ko not_active Ceased
- 2020-03-02 TW TW109106773A patent/TW202039507A/zh unknown
- 2020-03-02 TW TW109106772A patent/TW202045182A/zh unknown
-
2023
- 2023-05-19 JP JP2023083174A patent/JP2023096156A/ja active Pending
- 2023-06-22 JP JP2023102852A patent/JP2023112136A/ja active Pending
-
2024
- 2024-08-09 JP JP2024134396A patent/JP2024152860A/ja active Pending
-
2025
- 2025-02-18 JP JP2025024594A patent/JP2025075059A/ja active Pending
- 2025-05-26 AU AU2025203861A patent/AU2025203861A1/en active Pending
- 2025-05-26 AU AU2025203865A patent/AU2025203865A1/en active Pending